Edition:
United States

DelMar Pharmaceuticals Inc (DMPI.OQ)

DMPI.OQ on NASDAQ Stock Exchange Capital Market

0.70USD
18 Sep 2018
Change (% chg)

-- (--)
Prev Close
$0.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
30,843
52-wk High
$2.29
52-wk Low
$0.36

Chart for

About

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being... (more)

Overall

Beta: 1.74
Market Cap(Mil.): $15.41
Shares Outstanding(Mil.): 22.01
Dividend: --
Yield (%): --

Financials

  DMPI.OQ Industry Sector
P/E (TTM): -- 14.16 18.48
EPS (TTM): -0.65 -- --
ROI: -252.92 6.05 0.43
ROE: -- 7.81 16.38

BRIEF-Delmar Appoints Saiid Zarrabian Full-Time President And CEO

* DELMAR APPOINTS SAIID ZARRABIAN TO FULL-TIME PRESIDENT AND CEO

May 22 2018

BRIEF-DelMar Pharmaceuticals Reports Q3 Loss Per Share Of $0.13

* DELMAR PHARMACEUTICALS ANNOUNCES THIRD QUARTER FISCAL YEAR 2018 FINANCIAL RESULTS

May 17 2018

BRIEF-DelMar Pharmaceuticals Presents Positive Updates on 2 Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM

* DELMAR PHARMACEUTICALS PRESENTS POSITIVE UPDATES ON TWO ONGOING CLINICAL TRIALS WITH VAL-083 FOR TREATMENT OF MGMT-UNMETHYLATED GBM

Apr 17 2018

BRIEF-Delmar Pharmaceuticals To Increase Number Of Authorized Shares Of Stock, Par Value Of $0.001, Per Share From 50 Mln Shares To 70 Mln Shares

* TO INCREASE NUMBER OF AUTHORIZED SHARES OF STOCK, PAR VALUE OF $0.001, PER SHARE FROM 50 MILLION SHARES TO 70 MILLION SHARES Source text: (https://bit.ly/2GWHkzx) Further company coverage:

Apr 13 2018

Competitors

Earnings vs. Estimates